Thrombomodulin, plasminogen activator inhibitor type 1 (PAI-1) and fibronectin as biomarkers of endothelial damage in preeclampsia and eclampsia

International Journal of Gynecology and Obstetrics

Volumn 55, Issue 2, 1996, Pages 135-139

  Shaarawy, Mohamed ^a   El Didy, Hany ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Eclampsia; Fibronectin; Plasminogen activator inhibitor type 1; Preeclampsia; Thrombomodulin

Indexed keywords

BIOLOGICAL MARKER; FIBRONECTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOMODULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; ECLAMPSIA; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; FEMALE; HUMAN; IMMUNODIFFUSION; PREECLAMPSIA; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

EID: 0030297074     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7292(96)02755-5     Document Type: Article

References (16)

1. [1] Ballegeer V, Spitz L, Kieckens L, Moureau H, Van Assche A, Collen D. Predictive value of increased plasma levels of fibronectin in gestational hypertension. Am J Obstet Gynecol 1989; 161: 432.
2. [2] Bonnar J, Daly L, Sheppard B. Changes in fibrinolytic system during pregnancy. Semin Thromb Haemost 1990; 16: 221.
3. [3] Booth N, Simpson A, Croll A, Bennett B, Macgregor I. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 1988; 70: 327.
4. [4] Deng J, Bremme K, Hansson L, Blomback M. Plasma levels of Von Willebrand factor and fibronectin as markers of persisting endothelial damage in preeclampsia. Obstet Gynecol 1994; 84: 941.
5. [5] Eriksen H, Hansen P, Brock V, Jensen B. Fibronectin concentration in normal pregnancy and preeclampsia. Acta Obstet Gynecol Scand 1987; 66: 25.
6. [6] Estelles A, Gilabert J, Espana F, Aznar J, Galbis M. Fibrinolytic parameters in normotensive pregnancy with intrauterine fetal growth retardation and in severe preeclampsia. Am J Obstet Gynecol 1991; 165: 138.
7. [7] Friedman S, Schiff E, Emeis J, Dekker G, Sibai B. Biochemical correlation of endothelial involvement in severe preeclampsia. Am J Obstet Gynecol 1995; 172: 202.
8. [8] Halligan A, Bonnar J, Sheppard B, Darling M, Walshe J. Haemostatic, fibrinolytic and endothelial variables in normal pregnancy and preeclampsia. Br J Obstet Gynecol 1994; 101: 488.
9. [9] Hsu C, Irity B, Johnson T, Witter F, Hong S. Elevated circulating thrombomodulin in severe preeclampsia. Am J Obstet Gynecol 1993; 169: 148.
10. [10] Hsu C, Lucas B, Johnson T, Hong S, Chan D. Elevated urine thrombomodulin/creatinine ratio in severely preeclamptic pregnancies. Am J Obstet Gynecol 1994; 171: 854.
11. [11] Ishii H, Majerus P. Thrombomodulin is present in human plasma and urine. J Clin Invest 1985; 76: 2178.
12. + cellular fibronectin precedes the clinical signs of preeclampsia. Am J Obstet Gynecol 1990; 162: 358.
13. [13] Micheli M, De Franco A, Nitti M. Fibronectin levels in pregnancy and the puerperium. Clin Exp Obstet Gynecol 1989; 16: 59.
14. [14] Reith A, Booth N, Moore N, Cruickshank D, Bennett B. Plasminogen activator inhibitors (PAI-1 and PAI-2) in normal pregnancies, preeclampsia, and hydatidiform mole. Br J Obstet Gynecol 1993; 100: 370.
15. [15] Roberts J, Taylor R, Musci T, Rodgers G, Mclaughlin M. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989; 161: 1200.
16. [16] Simson J, Booth N, Moore N, Bennett B. The platelet and plasma pools of plasminogen activator inhibitor (PAI-1) vary independently in disease. Br J Haematol 1990; 75: 543.